Pharma Company Expands Capabilities with New Peptide Research Center Pharma Company Expands Capabilities with New Peptide Research Center The company's Price-Earnings (PE) Ratio stands at 165.54. DSIJ Intelligence / Saturday, April 5, 2025 / Article rating: 5.0 Major public shareholders include Tpg Asia Vii Sf Pte Ltd with 24.78 per cent, HBM Private Equity India with 1.99 per cent, Anitha Rudraraju Nandyala with 1.73 per cent, Raju Penmasta with 1.11 per cent and Penmasta Aruna with 1.02 per cent.
Can Sai Life Sciences ride the global CRDMO wave? A detailed IPO analysis Can Sai Life Sciences ride the global CRDMO wave? A detailed IPO analysis Sai Life Sciences Ltd, a prominent player in the CRDMO sector, is set to launch its IPO. Dive into the details of this ambitious offering, its financials, valuation, and whether it’s a wise investment for today’s market. DSIJ Intelligence / Wednesday, December 11, 2024 / Article rating: 4.8 Sai Life Sciences Ltd, a prominent player in the CRDMO sector, is set to launch its IPO. Dive into the details of this ambitious offering, its financials, valuation, and whether it’s a wise investment for today’s market.